<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00701597</url>
  </required_header>
  <id_info>
    <org_study_id>OPHT-020606</org_study_id>
    <nct_id>NCT00701597</nct_id>
  </id_info>
  <brief_title>Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma</brief_title>
  <official_title>Effects of Non-Specific Endothelin-A Receptor Blockade on Ocular Blood Flow in Patients With Glaucoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several lines of evidence suggest now that ocular perfusion abnormalities may contribute to&#xD;
      the progression of glaucoma. It has been hypothesised that increased endothelin-1 plasma&#xD;
      levels, as seen in patients with glaucoma, may be related to these alterations in ocular&#xD;
      blood flow. We could show in recent experiments that administration of ET-1 decreases ocular&#xD;
      blood flow, whereas blocking of the ET-A receptors do not affect basal vascular tone in&#xD;
      healthy subjects. In the current study we set out to evaluate the effect Bosentan, a&#xD;
      non-selective ETA-receptor antagonist in patients with open-angle glaucoma. This should allow&#xD;
      us to test the hypothesis that administration of an ET-1 receptor antagonist increases ocular&#xD;
      blood flow in patients with glaucoma.&#xD;
&#xD;
      Investigations will be done with a retinal vessel analyzer to determine retinal vessel&#xD;
      cross-sectional diameters, with laser Doppler flowmetry and laser Doppler velocimetry to&#xD;
      determine subfoveal macular blood flow and optic nerve head blood flow and with laser&#xD;
      interferometric measurements to determine fundus pulsation amplitude in the macula. The&#xD;
      intraocular pressure will be measured with applanation tonometry. This will be assessed at&#xD;
      baseline and in response to peroral application of Bosentan or placebo.&#xD;
&#xD;
      The study objective is therefor, to evaluate the contribution of ET-1 to ocular blood flow&#xD;
      dysregulation in patients with open-angle glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optic nerve head blood flow (Laser Doppler Flowmetry) Choroidal blood flow(Laser interferometry, Laser Doppler Flowmetry) Retinal blood flow(Laser Doppler velocimetry, Retinal Vessel analyzer) Intraocular pressure (Applanation tonometry)</measure>
    <time_frame>study 1: ocular blood flow measurements once; study day 2: basline measurements, and after 120min, 180min, 240min after medication intake</time_frame>
  </primary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Glaucoma</condition>
  <condition>Blood Flow Velocity</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bosentan</intervention_name>
    <description>Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Men and women aged over 18 years&#xD;
&#xD;
          -  Normal findings in the medical history and physical examination unless the&#xD;
             investigator considers an abnormality to be clinically irrelevant&#xD;
&#xD;
          -  Inclusion criteria for patients is primary open angle glaucoma defined as pathological&#xD;
             optic disc appearance and characteristic visual field loss&#xD;
&#xD;
          -  Men and women will be included in equal parts&#xD;
&#xD;
          -  Ametropia of less than 6 diopters and anisometropia of less than 2 diopters&#xD;
&#xD;
        Exclusion Criteria (glaucoma patients)&#xD;
&#xD;
          -  Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks&#xD;
             preceding the study&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions&#xD;
             known to interfere with distribution, metabolism or excretion of study drugs&#xD;
&#xD;
          -  Elevated liver enzymes AST and ALT&#xD;
&#xD;
          -  Blood donation during the previous 3 weeks&#xD;
&#xD;
          -  Ametropy more than 6 dpt&#xD;
&#xD;
          -  Systemic treatment with, oral antikoagulation, Glibenclamid or vasoactive drugs&#xD;
&#xD;
          -  History of IOP &gt; 30 (untreated)&#xD;
&#xD;
          -  Presence of intraocular pathology other than glaucoma&#xD;
&#xD;
          -  Advanced visual field defect defined as MD &gt;-10&#xD;
&#xD;
          -  Presence of PEX (pseudoexfoliation) glaucoma and pigment glaucoma&#xD;
&#xD;
          -  Ophthalmolgical surgery (including argon laser trabeculoplasty (ALT), trabeculectomy,&#xD;
             deep sclerectomy) within the last 6 months before the study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
        Exclusion criteria (healthy controls)&#xD;
&#xD;
          -  Abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks&#xD;
             preceding the study&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness in the 3 weeks before the first study day&#xD;
&#xD;
          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions&#xD;
             known to interfere with distribution, metabolism or excretion of study drugs&#xD;
&#xD;
          -  Blood donation during the previous 3 weeks&#xD;
&#xD;
          -  Ametropy more than 6 dpt&#xD;
&#xD;
          -  Systemic treatment with oral anticoagulation, Glibenclamid or vasoactive drugs&#xD;
&#xD;
          -  Elevated liver enzymes AST and ALT&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Fuchsjager-Mayrl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology, Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>June 18, 2008</study_first_submitted>
  <study_first_submitted_qc>June 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2008</study_first_posted>
  <last_update_submitted>June 18, 2008</last_update_submitted>
  <last_update_submitted_qc>June 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Gabriele Fuchsjaeger-Mayrl</name_title>
    <organization>Departnebt of Clinical Pharmacology, Medical University of Vienna</organization>
  </responsible_party>
  <keyword>ocular blood flow dysregulation, glaucoma, endothelin-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

